Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + SBRT in HER2-Negative Breast Cancer Insensitive to Neoadjuvant Chemotherapy
NCT07410234Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of toripalimab in breast cancer (6 cohorts), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Pathologic complete response at 12 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07410234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07410234.